Compare Amphastar Pharmaceuticals Inc (AMPH) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Teladoc Health Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Teladoc Health Inc trades at $9.22 (market cap $1.68B). The key difference: Teladoc Health Inc is far larger — about 2× Amphastar Pharmaceuticals Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TDOC | |
|---|---|---|
Market Cap | $826.08M | $1.68B |
Sector | Health | Health |
52-Week High | $30.81 | $9.52 |
52-Week Low | $16.87 | $4.47 |
Enterprise Value | $1.22B | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Teladoc Health (TDOC) trades at $9.28, up 0.76% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.53B in 2025 with a net loss of $200.32M, though losses are narrowing year-over-year. Recent news highlights expansion through the Walmart partnership and ongoing cost-cutting initiatives. Valuation ratios show a P/S of 0.65 and EV/EBITDA of 9.14, suggesting potential undervaluation relative to sales.
Outlook remains cautious despite improving fundamentals; analyst consensus is mixed with 35.7% buy ratings but a $8.75 price target below current levels. Key risks include persistent net losses, competitive pressures in telehealth, and high debt levels. The stock's trajectory hinges on achieving profitability and sustaining growth amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
